StreetInsider.com News Articles

Inova Technology, Inc. (INVA) PT Raised to $32 at Cantor Fitzgerald on Improved Outlook

Thu, 26 Feb 2026 10:03:14 -0500

(Updated - February 26, 2026 10:03 AM EST)

Cantor Fitzgerald analyst Steve Seedhouse raised the price target on Inova Technology, Inc. (NASDAQ: INVA) to $32.00 (from $31.00) while maintaining a Overweight rating.

The analyst commented, "We remain Overweight on INVA following 4Q25 earnings. 4Q25 revenue of $114.6M exceeded our ~$103M, mainly helped by the continued inventory build of XacDuro in China, which may result in higher royalties and milestones in 2026 and beyond. In the U.S., 2025 Innoviva Specialty Therapeutics (IST) revenue of $119M handily beat last year's guidance of $100M + and grew ~41% y/y. For 2026, Innoviva is targeting >$150M

Inova Technology, Inc. (INVA) PT Raised to $32 at Cantor Fitzgerald on Improved Outlook

Thu, 26 Feb 2026 10:03:14 -0500

(Updated - February 26, 2026 10:03 AM EST)

Cantor Fitzgerald analyst Steve Seedhouse raised the price target on Inova Technology, Inc. (NASDAQ: INVA) to $32.00 (from $31.00) while maintaining a Overweight rating.

Innoviva (INVA) Reports Q4 EPS of $1.94

Thu, 26 Feb 2026 02:42:04 -0500

Innoviva (NASDAQ: INVA) reported Q4 EPS of $1.94. Revenue for the quarter came in at $114.6 million versus the consensus estimate of $101.53 million.

For earnings history and earnings-related data on Innoviva (INVA) click here.

Form 8-K Innoviva, Inc. For: Feb 25

Wed, 25 Feb 2026 16:58:00 -0500

si-local-file:///var/storage/secattach/20260225/26061315.html

Form 8-K Innoviva, Inc. For: Feb 25

Wed, 25 Feb 2026 16:58:00 -0500

si-local-file:///var/storage/secattach/20260225/26061315.html

Form 10-K Innoviva, Inc. For: Dec 31

Wed, 25 Feb 2026 16:32:00 -0500

http://archive.fast-edgar.com/20260225/AQ2VK62CZZ2RBZZ222ZG2ZYQMDBIZZ22D286

Filed on: February 25, 2026

Form 10-K Innoviva, Inc. For: Dec 31

Wed, 25 Feb 2026 16:32:00 -0500

http://archive.fast-edgar.com/20260225/AQ2VK62CZZ2RBZZ222ZG2ZYQMDBIZZ22D286

Filed on: February 25, 2026

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Wed, 25 Feb 2026 16:05:00 -0500

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year

IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth

IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea

$125 million share repurchase program initiated in the fourth quarter

Form 4 Innoviva, Inc. For: Feb 20 Filed by: Zhen Marianne

Tue, 24 Feb 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260224/26051736.html

Form 4 Innoviva, Inc. For: Feb 20 Filed by: Zhen Marianne

Tue, 24 Feb 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260224/26051736.html